Forbion Capital Partners said it closed its Forbion Capital Fund II Co-invest Fund I with 75 million Euros (US$84 million). The Co-Invest fund was set up to allow Forbion’s existing LPs to back later-stage, de-risked companies within the existing FCF II portfolio with additional (growth) capital. The pool will invest in up to six existing FCF II portfolio companies, alongside FCF II. Forbion is a Life Sciences venture capital firm with offices in Naarden, The Netherlands
Naarden, The Netherlands, 10 September 2015 – Expanding on its successful co-investment program, Forbion is pleased to announce the closing of its Forbion Capital Fund II Co-invest Fund I (FCF II Co-Invest) at EUR 75M. This new fund vehicle has been set up to allow Forbion’s existing LPs to back later-stage, de-risked companies within the existing FCF II portfolio with additional (growth) capital.
The new Co-Invest Fund will invest in up to six existing FCF II portfolio companies, alongside FCF II, in what are likely to be the final financing rounds by these companies before exit.
“The concept of deploying additional capital in later-stage, de-risked portfolio companies that the Forbion team has a deep understanding of, and involvement with, has proven a successful strategy for our previous Co-Invest funds, which have invested in companies including Biovex and uniQure,” commented Sander Slootweg, Managing Partner at Forbion Capital Partners.
“We are pleased to see that among others, our major investors Coller Capital, Hamilton Lane and KLP have again subscribed to this new fund,” added Martien van Osch, Managing Partner at Forbion. “The new co-invest fund has hit the ground running by already deploying capital in Cellnovo, which subsequently went public on Euronext Paris, and in Dezima Pharma and Exosome Diagnostics.”
“As a major secondaries player, what we like about this particular strategy is that through FCF II Co-Invest we are investing in later-stage, de-risked portfolio companies that the Forbion team has been actively working with for several years. Moreover, the additional capital is deployed quickly and there is no ‘blind pool’ risk, typically associated with primary funds,” commented Remco Haaxman, Investment Principal at Coller Capital.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
– ENDS –
About Forbion Capital Partners
Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, Munich, Germany and representation in Boston, US. Forbion invests in life sciences companies in drug discovery & development as well as medical device companies addressing substantial unmet medical needs. Forbion’s investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda (ACOR), Fovea, Insmed (INSM), PanGenetics, Argenta Discovery, BioVex, Pathway Medical, CircuLite, bluebird bio (BLUE), uniQure (QURE), Argos (ARGS), arGEN-X (ARGX.BR), Santaris, PneumRx, AM Pharma and Promedior. Forbion also operates a joint venture with BioGeneration Ventures, who manage two separate seed and early stage funds focused on Benelux. Including the new fund FCF III, Forbion manages EUR 635M across six funds. Its investors include the EIF through its European Recovery Programme (ERP), LfA and Dutch Venture Initiative (DVI) facilities and the KFW through the ERP – Venture Capital Fondsfinanzierung facility.
For further information please visit www.forbion.com
Issued for and on behalf of Forbion by Instinctif Partners.